GLIORESOLVE Holds 4th Plenary Meeting in Dublin

The GLIORESOLVE consortium came together for its 4th Plenary Meeting on 23 June 2026, hosted by the Royal College of Surgeons in Ireland (RCSI) in Dublin. The meeting brought together doctoral candidates, principal investigators, consortium partners and Associated Partners in a hybrid format to review progress across the project as it enters its final phase. Representatives from Associated Partner Arjuna Therapeutics also participated, contributing to discussions on the project's scientific progress and future opportunities.

The morning focused on consortium management, with updates on project activities, deliverables and milestones, financial planning, preparations for the final reporting period, and meetings of the network's governance committees, including the Research and Ethics, Training, Dissemination and Outreach, and IPR, Exploitation and Commercialisation Committees.

A major highlight of the day was a series of scientific presentations delivered by all ten GLIORESOLVE doctoral candidates. Across three dedicated sessions, the researchers presented the latest findings from their projects, covering topics including tumour microenvironment (TME) subtype-specific therapies, immunotherapy, organ-on-chip models, computational multi-omics, personalised medicine and novel therapeutic strategies for glioblastoma. The presentations demonstrated the breadth and quality of research being undertaken across the network and generated lively discussion between students, supervisors and consortium partners.

The plenary meeting also provided an important opportunity to look beyond the lifetime of the project. Alongside reviewing progress and coordinating activities for the final months of GLIORESOLVE, partners discussed plans for future collaborative proposal development, identifying opportunities to build on the network's scientific achievements and strengthen long-term collaborations. The day concluded with a network dinner in Dublin city centre, providing an informal setting for further scientific discussion and networking.

As GLIORESOLVE approaches its conclusion, the consortium remains committed to advancing our understanding of glioblastoma biology and translating these discoveries into innovative, precision-targeted therapies for patients while building lasting collaborations that will continue beyond the project.